Recently, team of Associate Professor Huang Jin from the Department of Oncology of Xiangya Hospital, Central South University, has made important progress in the pharmacoeconomics study of durvalumab in the first-line treatment of extensive-stage small cell lung cancer (SCLC), and published an online original article titled Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer in Journal of the National Comprehensive Cancer Network (IF=11.908). Associate Professor Huang is the corresponding author. Ding Dong, a graduate student, and Dr.Hu Huabin from the Department of Medical Oncology, the Sixth Affiliated Hospital of Sun Yat-sen University are the co-first authors. Xiangya Hospital of Central South University is the first affiliation and the corresponding affiliation.
Tumor immunotherapy has become the most successful and revolutionary strategy for cancer treatment in recent years. The second-generation immune checkpoint inhibitors represented by PD-1 and PD-L1 exert prominent therapeutic effects on malignant tumors. Clinical trial results have manifested that PD-L1 inhibitor durvalumab plus chemotherapy can significantly prolong the survival of patients with extensive-stage small cell lung cancer. However, from the perspective of drug value, whether its price reflects its potential value is a crucial issue to be resolved urgently. The pharmacoeconomic analysis of durvalumab plus chemotherapy was, for the first time, conducted internationally in this research. The results demonstrated that compared with chemotherapy alone, durvalumab plus chemotherapy has no cost-effectiveness. When health decision-makers consider including durvalumab into the scope of medical insurance reimbursement, the price of durvalumab should be reduced to the level that can reflect its clinical value, thus realizing value-based medical and health services.
There is no doubt that breakthroughs and innovations of tumor immunotherapy have brought hope of survival to patients with malignant tumors. However, availability and affordability of representative novel anti-cancer agents still need to be further improved. How to reconcile the contradiction between short-term financial pressure and long-term health benefits is a problem of the global health system. Based on the clinical value and high costs of immunotherapy drugs, the series of researches conducted by Associate Professor Huang"s team in recent years has focused on investigating the economic benefits of immunotherapy drugs for malignant tumors. A large number of studies have been conducted in fields where immunotherapy has made significant progress, such as lung cancer and kidney cancer. These studies provide references for formulation of the medicine list covered by the medical-insurance system, support China"s medical insurance payment and bargaining policies for domestic and foreign innovative drugs, and guide the clinical rational use of drugs for patient benefits.
The research team has made remarkable achievements and important contributions in promoting the development of domestic pharmacoeconomics evaluation methods in line with international standards, providing economic evidence support for national and provincial medical insurance as well as health-related decision-making departments, offering medical institutions with pharmacoeconomics capacity-building support and hospital decision support, and providing medicine and other health technology economic evaluation research services for domestic and foreign pharmaceutical and medical device companies, which have been widely concerned and highly recognized by counterparts in China and foreign countries. The team will further commit to the pharmacoeconomics research of various novel anti-tumor agents, pay attention to the frontier issues in the research field, expand international influence, and promote the construction and development of first-class medical disciplines.
Link to the original text:
Introduction of Associate Professor Huang Jin"s Team
Team leader: Huang Jin, M.D., Associate Professor, Associate Chief Physician, Master"s Mentor.
She is currently the Associate Chief Physician and Associate Professor of the Department of Oncology, Xiangya Hospital of Central South University. She is also a member of the Chinese Anti-Cancer Association of Nutrition and Cancer Treatment Support Committee, a young member of the Cancer Drug Clinical Research Committee of China Anti-Cancer Association, a young member of the club chemotherapy Branch Youth Committee of Chinese Medical Association, Hunan Province, a vice director member of Chinese Anti-Cancer Association of Nutrition and Cancer Treatment Support Committee, a vice director member of Youth Committee of Hunan Molecular Targeted Therapy Committee of Chinese Anti-Cancer Association, and a standing committee member of International Hepatobiliary and Pancreatic Association China Branch Metastatic Liver Cancer Committee among multiple academic positions.
The research team led by Associate Professor Huang is dedicated to the integrated prevention and treatment of gastrointestinal malignant tumors, and has been committed to the basic research of immunotherapy drug resistance mechanism of malignant tumors and pharmacoeconomics of immunotherapy. She has published more than 20 SCI papers as the first author and corresponding author on international journals, such as Gut (IF: 23.058), Journal of the National Comprehensive Cancer Network (IF: 11.908), Lung Cancer (IF: 5.705), Front Oncol (IF: 6.244), and The Oncologist (IF: 5.025). She is also in charge of a number of national scientific research projects, including the Youth Program of National Natural Science Foundation of China, the scientific research support project of the Hunan Provincial Department of Finance, the scientific research project of the Hunan Provincial Department of Science and Technology, the Wu Jieping Medical Fund of the Ministry of Health, and other provincial-level projects and talent projects, and trained 5 outstanding master graduates of clinical medicine, including Ding Dong, from Central South University.
Xiangya Hospital Central South University
All Rights Reserved.